Molecular Partners Ag (MOLN) Cash from Operations (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Cash from Operations of 18188.38 for Q1 2026, up 4.26% year-over-year from 17445.58 in Q1 2025, and up 99.97% quarter-over-quarter from 64081030.6 in Q4 2025.
Molecular Partners Ag (MOLN) Cash from Operations (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Cash from Operations for 7 consecutive years, with 18188.38 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 4.26% year-over-year to 18188.38; the TTM figure through Mar 2026 stood at 62854547.06 (up 4.83% YoY), while the FY2025 annual figure was 64131210.02, up 5.18% from the prior year.
- Cash from Operations improved to 18188.38 in Q1 2026 per MOLN's latest filing, from 64081030.6 in the prior quarter.
- Across five years, Cash from Operations topped out at 156597882.47 in Q2 2022 and bottomed at 156201913.72 in Q3 2022.
- Historically, Cash from Operations has averaged 4196191.7 across 5 years, with a median of 18997.24 in 2025.
- On a YoY basis, Cash from Operations climbed as much as 635.85% in 2022 and fell as far as 373.36% in 2022.
- Molecular Partners Ag's Cash from Operations stood at 122936223.52 in 2022, then tumbled by 154.07% to 66471055.32 in 2023, then retreated by 1.67% to 67580315.95 in 2024, then rose by 5.18% to 64081030.6 in 2025, then soared by 99.97% to 18188.38 in 2026.
- Business Quant data shows MOLN's Cash from Operations at 18188.38 in Q1 2026, 64081030.6 in Q4 2025, and 37678168.26 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.54 Bn | 130.69 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.89 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.84 Bn | 59.65 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.53 Bn | 51.39 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 728.46 Mn |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | -18,188.38 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18,188.38 |
| Mar 31, 2026 | -18,188.38 |
| Dec 31, 2025 | -64.08 Mn |
| Dec 31, 2025 | -64.08 Mn |
| Sep 30, 2025 | 37.68 Mn |
| Sep 30, 2025 | 37.68 Mn |
| Jun 30, 2025 | -36.43 Mn |
| Jun 30, 2025 | -36.43 Mn |
| Mar 31, 2025 | -18,997.24 |
| Mar 31, 2025 | -18,997.24 |
| Dec 31, 2024 | -67.58 Mn |
| Dec 31, 2024 | -67.58 Mn |
| Sep 30, 2024 | 37.77 Mn |
| Sep 30, 2024 | 37.77 Mn |
| Jun 30, 2024 | -36.22 Mn |
| Jun 30, 2024 | -36.22 Mn |
| Mar 31, 2024 | -19,532.74 |
| Mar 31, 2024 | -19,532.74 |
| Dec 31, 2023 | -66.47 Mn |
| Dec 31, 2023 | -66.47 Mn |